Equities

Vilin Bio Med Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
VILINBIO:NSI

Vilin Bio Med Ltd

Actions
  • Price (INR)32.30
  • Today's Change-1.65 / -4.86%
  • Shares traded8.00k
  • 1 Year change+59.90%
  • Beta--
Data delayed at least 15 minutes, as of Feb 16 2026 08:17 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Vilin Bio Med Limited is an India-based company engaged in the business of manufacturing and selling pharmaceutical products. The Company is engaged in the manufacturing of pharmaceutical formulations, such as oral liquids, dry syrups, sachets, external preparations, beta and non-beta lactam tablets and capsules and nutritional food supplements. Its products include cardiovascular drugs, musculoskeletal drugs, antibiotic drugs, central nervous system drugs, alimentary system drugs, genitourinary tract drugs, respiratory system and anti-allergic drugs, anti-diabetic drugs, multi-vitamins, minerals and amino acids supplements, miscellaneous drugs, liquid orals and external preparations. Its cardiovascular drugs include ATORVOSTATIN + Aspirin Capsules, Dapagliflozin 10 milligrams (mg) tablets, Fluvastatin Tablets 40 mg, PRASUGREL 10 mg tablets, and Cilnidipine five mg tablets. Its external preparations include calamine lotion, ciprofloxacin, fluocinolone acetonide and others.

  • Revenue in INR (TTM)199.81m
  • Net income in INR2.51m
  • Incorporated2005
  • Employees--
  • Location
    Vilin Bio Med LtdSy no 115, Hanumanji ColonyOpp Sub Register Office, Old BowenpallyHYDERABAD 500009IndiaIND
  • Phone+91 9 248000756
  • Websitehttps://www.vilinbiomed.co.in/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
JFL Life Sciences Ltd800.66m47.93m395.94m39.008.21--6.620.49451.461.4624.37------------5.83--10.6422.2318.286.025.73--5.95----76.2522.1525.7263.09-32.30--
Jupiter Bioscience Ltd-100.00bn-100.00bn399.59m----------------------------5.42--5.61--61.37--17.32------10.4842.4329.3020.9222.8255.40-16.74
Lasa Supergenerics Ltd952.91m-361.68m447.40m66.00--0.7941--0.4695-7.57-7.5719.5811.250.87056.0636.0814,437,960.00-33.04-6.42-46.76-8.5422.2828.58-37.96-8.050.5203-14.700.1152--36.53-3.1632.09------
Vilin Bio Med Ltd199.81m2.51m473.60m--188.202.04133.302.370.18040.180414.3416.640.68453.653.25--0.85921.811.082.706.6021.721.262.714.161.190.0193---6.30-2.5137.626.62130.50--
Mangalam Drugs and Organics Ltd2.38bn-309.21m517.43m414.00------0.217-19.53-19.53150.57--------5,758,911.00--2.90--5.3439.1529.02-12.972.46---0.9827-----13.662.42174.27-4.0223.85--
Biofil Chemicals and Pharmaceuticals Ltd425.20m28.59m584.39m26.0020.492.7418.421.371.751.7525.8713.090.87317.841.2816,353,690.005.872.1314.164.335.228.636.722.331.338.280.0009---16.572.38-21.36-14.31-13.50--
Vineet Laboratories Ltd570.37m-166.97m590.98m----2.36--1.04-15.30-15.3052.0813.020.57851.014.23---16.94-1.82-54.66-5.754.8619.76-29.27-1.090.1186-3.060.7505---50.20---2,065.83------
Data as of Feb 16 2026. Currency figures normalised to Vilin Bio Med Ltd's reporting currency: Indian Rupee INR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.